Banco Macro S.A.
NYSE:BMABanks - Regional
+$1.53 today
- Market cap
- $3.45B
- Beta
- 0.50
- P/E (TTM)
- 25.5
- EPS (TTM)
- $579.33
- Dividend yield
- 4.63%
Volume 0.27M
Average 0.32M
BMA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Banco Macro S.A.NYSE: BMA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of ARS 328.99B rose 14.7% year over year, ahead of the +5.4% change in trailing-twelve-month EBITDA. Sequentially, it rose 26.9% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- EBITDA amounted to 11.8% of revenue in FY2025, up 4.1 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of ARS 1.17T (+70.0%) for the fiscal year ending Dec 2026, a step up from the +38.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- ARS 328.99B+26.9% QoQ
- Last fiscal yearDec 2025
- ARS 688.93B+38.3% YoY
- LTMJun 2026
- ARS 794.1B+5.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +14.7% | +6561.9% | +6547.2 pp |
| 1 year | +38.3% | +70.0% | +31.7 pp |
| 3-year CAGR | +15.4% | +45.8% | +30.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
ARS · from the income statement
- Latest · FY2025
- 688.93B ARS
- Year-over-year change
- +38.3%
- 4-year CAGR
- +38.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 688.93B | +38.3% |
| FY2024 | 2024-12-31 | 498.16B | -75.2% |
| FY2023 | 2023-12-31 | 2.01T | +348.0% |
| FY2022 | 2022-12-31 | 448.56B | +137.1% |
| FY2021 | 2021-12-31 | 189.17B | — |
EBITDA vs competitors
How BMA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.4% is the 7th highest of 8, against a peer median of +32.4%.
- EBITDA amounts to 16.5% of revenue for BMA, versus a peer median of 39.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | COP 11.04T COP | +118.2% | -19.4% | 24.0% | |
| LTM Jun 2026 | ARS 794.1B ARS | +5.4% | +15.4% | 16.5% | |
| LTM Sep 2026 | $1.43B USD | +84.1% | +23.1% | 39.1% | |
| LTM Sep 2026 | $946.47M USD | +32.4% | +1.6% | 47.0% | |
| LTM Sep 2026 | $820.31M USD | +20.8% | +6.0% | 30.3% | |
| LTM Sep 2026 | $751.56M USD | +38.0% | +5.7% | 42.0% | |
| LTM Sep 2026 | $650.65M USD | +7.3% | +13.9% | 43.4% | |
| LTM Sep 2026 | $513.28M USD | -24.9% | -1.9% | 17.0% | |
| Peer median (excluding BMA) | — | +32.4% | +5.7% | 39.1% | |
Competitors are the stored peer set for BMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.7T | 5.37T | 9.69T | 6.46T | 5.82T |
| Cost of Revenue | 589.91B | 2.14T | 3.65T | 2.05T | 2.88T |
| Gross Profit | 1.11T | 3.23T | 6.04T | 4.41T | 2.94T |
| Gross Margin | 65.3% | 60.2% | 62.3% | 68.3% | 50.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 350.72B | 351.04B | 923.47B | 1.02T | 1.58T |
| Operating Expenses | 965.84B | 2.83T | 4.16T | 4.05T | 2.34T |
| Depreciation & Amortization | 43.22B | 47.49B | 126.52B | 138.14B | 93.02B |
| EBITDA | 189.17B | 448.56B | 2.01T | 498.16B | 688.93B |
| EBITDA Margin | 11.1% | 8.4% | 20.7% | 7.7% | 11.8% |
| Operating Income | 145.94B | 401.07B | 1.88T | 360.01B | 595.61B |
| Operating Margin | 8.6% | 7.5% | 19.4% | 5.6% | 10.2% |
| Interest Income | 1.37T | 4.17T | 5.35T | 3.55T | 5.83T |
| Interest Expense | 574.16B | 2.09T | 3.55T | 1.94T | 2.25T |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 299.45M |
| Income Before Tax | 145.94B | 401.07B | 1.88T | 360.01B | 595.91B |
| Pre-Tax Margin | 8.6% | 7.5% | 19.4% | 5.6% | 10.2% |
| Income Tax Expense | 7.19B | 124.57B | 614.79B | 33.52B | 256.92B |
| Net Income | 138.74B | 276.45B | 1.27T | 325.5B | 337.27B |
| Net Margin | 8.2% | 5.1% | 13.1% | 5.0% | 5.8% |
| EPS (Basic) | 457.80 | 846.10 | 22,388.80 | 5,090.60 | 5,281.60 |
| EPS (Diluted) | 457.80 | 846.10 | 22,388.80 | 5,090.60 | 5,281.60 |
| Weighted Avg Shares | 63.94M | 63.94M | 63.94M | 63.94M | 63.94M |
| Weighted Avg Shares (Diluted) | 63.94M | 63.94M | 63.94M | 63.94M | 63.94M |
Banco Macro S.A.
NYSE:BMA
Intrinsic Alpha fair value
Locked
Current Price
$53.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.